Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q2 2024 · 10-Q
Revenue$156.00$156.00— vs Q2 2023 Net Income-$54.80K-$54.80KN/M vs Q2 2023 EPS Diluted$0.00$0.00— vs Q2 2023 Operating Income-$54,800N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-35128.2%
Net margin-35128.2%
ended Jun 30, 2024 · filed Sep 18, 2024 · 80 d after period end